Top Page
Can-Fite BioPharma
(CANF)
Can-Fite BioPharma (CANF) vs. SPDR S&P 500 ETF (SPY)
Can-Fite BioPharma Business Overview & Revenue Model
Can-Fite BioPharma Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 560.00K | 674.00K | 743.00K | 810.00K | 853.00K | 763.00K |
| Gross Profit | 560.00K | 674.00K | 743.00K | 810.00K | 853.00K | 763.00K |
| EBITDA | -8.90M | -8.12M | -8.18M | -10.08M | -12.83M | -14.13M |
| Net Income | -8.80M | -7.88M | -7.63M | -10.17M | -12.60M | -14.44M |
Balance Sheet | ||||||
| Total Assets | 7.72M | 9.12M | 9.99M | 9.28M | 20.25M | 9.52M |
| Cash, Cash Equivalents and Short-Term Investments | 6.46M | 7.89M | 8.92M | 7.98M | 19.14M | 8.34M |
| Total Debt | 90.00K | 104.00K | 40.00K | 62.00K | 124.00K | 67.00K |
| Total Liabilities | 3.54M | 3.68M | 3.75M | 4.81M | 5.87M | 3.45M |
| Stockholders Equity | 4.18M | 5.44M | 6.24M | 4.47M | 14.38M | 6.07M |
Cash Flow | ||||||
| Free Cash Flow | -8.36M | -7.64M | -8.44M | -10.81M | -9.87M | -12.09M |
| Operating Cash Flow | -8.35M | -7.64M | -8.44M | -10.80M | -9.86M | -12.06M |
| Investing Cash Flow | -2.00K | 1.50M | 498.00K | 9.50M | -14.51M | -26.00K |
| Financing Cash Flow | 10.08M | 6.71M | 9.14M | 0.00 | 20.46M | 17.68M |
Can-Fite BioPharma Technical Analysis
Can-Fite BioPharma Risk Analysis
Can-Fite BioPharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $14.01M | -0.77 | -317.47% | ― | -100.00% | 58.50% | |
43 Neutral | $3.42M | -0.07 | -154.50% | ― | ― | 54.25% | |
41 Neutral | $5.68M | ― | ― | ― | ― | ― | |
41 Neutral | $7.84M | -0.10 | -270.74% | ― | ― | 72.88% |
Can-Fite BioPharma Corporate Events
On December 26, 2025, Can-Fite BioPharma announced that Brazil’s patent office granted a patent protecting the use of its A3 adenosine receptor agonist technology for the treatment of sexual dysfunction, extending its intellectual property coverage to one of Latin America’s largest pharmaceutical markets. The patent reinforces the therapeutic potential of Can-Fite’s A3AR platform in sexual health, complements its broader oncology and inflammatory disease programs, and may enhance the company’s strategic positioning and future commercial or partnering prospects in the region by leveraging preclinical and clinical data that link A3 receptor activation to vascular and metabolic pathways underlying erectile and sexual function.
The most recent analyst rating on (CANF) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
On December 23, 2025, Can-Fite BioPharma announced that, following shareholder approval on November 10, 2025, its board authorized a 1-for-3,000 reverse split of the company’s ordinary shares and a concurrent change in the ratio of ordinary shares underlying its American Depositary Shares (ADSs). The reverse split, which will reduce the total number of outstanding ordinary shares and proportionally cut authorized share capital from 42 billion to 14 million, will take effect on the Tel Aviv Stock Exchange in early January 2026, with first trading in the consolidated shares set for January 5, 2026, while the ADS ratio change to one ADS representing two ordinary shares—operationally a one‑for‑twenty ADS split—will become effective on NYSE American the same day, preserving shareholders’ proportional ownership and voting power aside from minor rounding effects and aiming to support a higher per‑ADS trading price and continued market listing stability.
The most recent analyst rating on (CANF) stock is a Sell with a $0.24 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
On December 16, 2025, Can-Fite BioPharma Ltd. provided an update on its clinical and financial status. The company is actively enrolling patients in pivotal Phase III studies for its Namodenoson drug candidate in advanced hepatocellular carcinoma and Piclidenoson for psoriasis. Additionally, Namodenoson is in Phase II trials for metabolic dysfunction-associated steatohepatitis and pancreatic cancer. Financially, Can-Fite reported having $6.45 million in cash and cash equivalents as of June 30, 2025, and raised additional funds through a public offering and ATM facility. These developments reflect Can-Fite’s strategic focus on addressing unmet medical needs with its drug candidates, potentially enhancing its market position and stakeholder value.
The most recent analyst rating on (CANF) stock is a Hold with a $0.37 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
On November 18, 2025, Can-Fite BioPharma Ltd. announced an agreement with a warrant holder to reduce the exercise price of warrants for 16,666,666 American Depositary Shares from $0.60 to $0.467 per ADS. This move, in exchange for the waiver of certain standstill provisions by the holder, could potentially enhance the attractiveness of the warrants and improve liquidity, reflecting a strategic decision to adjust financial terms in response to market conditions.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
On November 20, 2025, Can-Fite BioPharma Ltd. announced that its erectile dysfunction treatment, CF602, received a Notice of Allowance for a patent in Brazil. This patent expands CF602’s intellectual property protection beyond the U.S. and Europe, addressing a significant market need for diabetic patients and non-responders to existing ED drugs. CF602, an A3 adenosine receptor modulator, has shown promising results in preclinical studies, potentially offering an alternative to current ED treatments.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
On November 18, 2025, Can-Fite BioPharma Ltd. announced a significant milestone in its treatment of advanced liver cancer with Namodenoson. A patient treated in a Phase II study has achieved a 9-year survival with a complete response, remaining cancer-free. This breakthrough underscores Namodenoson’s potential as a potent anti-cancer agent with excellent tolerability. The company is currently enrolling patients for a pivotal Phase III trial in Europe, Israel, and the U.S., targeting hepatocellular carcinoma as a second or third-line treatment. Namodenoson holds Orphan Drug and Fast Track status with the FDA and EMA, highlighting its promising role in the liver cancer treatment market, which is projected to reach $6.1 billion by 2027.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
On November 10, 2025, Can-Fite BioPharma Ltd. held a Special General Meeting of Shareholders where all proposed resolutions were approved. This approval marks a significant step for the company as it aligns with their strategic plans and could potentially impact their market positioning and stakeholder interests.
The most recent analyst rating on (CANF) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
On November 3, 2025, Can-Fite BioPharma Ltd. held a Special General Meeting of Shareholders, which was adjourned due to a lack of quorum. The meeting is rescheduled to reconvene on November 10, 2025, at the company’s offices in Ramat Gan, Israel. This adjournment may impact the company’s decision-making processes and timelines, potentially affecting its strategic operations and stakeholder interests.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
On October 3, 2025, Can-Fite BioPharma Ltd. announced it will hold a Special General Meeting of Shareholders on November 3, 2025, at its offices in Ramat Gan, Israel. The meeting will address two key proposals: increasing the company’s authorized share capital by 22 billion shares and approving a reverse stock split at a ratio of 1:3000. These actions are intended to enhance the company’s capital structure and potentially improve its market position. Shareholders and American Depositary Shareholders are invited to vote on these proposals, which are recommended by the company’s Board of Directors.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.